The FDA has approved a new drug called Hepzato (melphalan) for adults with a rare eye cancer called uveal melanoma that has spread to the liver. This drug is given directly into the liver through a special delivery system. It is for patients whose liver tumors affect less than half of the liver and whose cancer has not spread elsewhere, or has only spread to areas like bone, lymph nodes, skin, or lung that can be removed or treated with radiation.
Hepzato is given every 6 to 8 weeks for up to 6 treatments. The dose is based on ideal body weight, with a maximum of 220 mg per treatment. Doctors must complete special training before giving this drug.
This approval is important because uveal melanoma that spreads to the liver is hard to treat, and there are few options. Hepzato offers a targeted treatment that may help control the disease. However, it is not a cure, and it is only for certain patients who meet specific criteria.
If you or a loved one has uveal melanoma that has spread to the liver, talk to your doctor about whether Hepzato might be an option. Your doctor can help you understand the risks and benefits based on your individual situation.